Literature DB >> 20132118

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

Jennifer Baker1, Petrie M Rainey, David E Moody, Gene D Morse, Qing Ma, Elinore F McCance-Katz.   

Abstract

To improve outcomes among injection drug users with HIV and/or chronic hepatitis B, it is important to identify drug interactions between antiretroviral and opiate therapies. We report the results of a study designed to examine the interaction between buprenorphine and the nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine (ddI), lamivudine (3TC), and tenofovir (TDF). Opioid-dependent, buprenorphine/naloxone-maintained, HIV-negative volunteers (n = 27) participated in two 24-hour sessions to determine (1) pharmacokinetics of buprenorphine alone and (2) pharmacokinetics of both buprenorphine and either ddI, 3TC, or TDF. Among buprenorphine/naloxone-maintained study participants, no significant changes in buprenorphine pharmacokinetics were observed following ddI, 3TC, or TDF administration. Buprenorphine had no significant effect on NRTI concentrations. Concomitant use of buprenorphine with ddI, 3TC, or TDF results in neither a significant pharmacokinetic nor pharmacodynamic interaction.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20132118      PMCID： PMC3723405          DOI： 10.1111/j.1521-0391.2009.00004.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN： 1055-0496


  41 in total

1.  Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Authors:  Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

Authors:  Naser L Rezk; Richard R Tidwell; Angela D M Kashuba
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2003-07-05       Impact factor: 3.205

3.  A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.

Authors:  Andrea A Howard; Julia H Arnsten; Yungtai Lo; David Vlahov; Josiah D Rich; Paula Schuman; Valerie E Stone; Dawn K Smith; Ellie E Schoenbaum
Journal:  AIDS       Date:  2002-11-08       Impact factor: 4.177

4.  Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir.

Authors:  P A Bart; P G Rizzardi; S Gallant; K P Golay; P Baumann; G Pantaleo; C B Eap
Journal:  Ther Drug Monit       Date:  2001-10       Impact factor: 3.681

5.  The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz.

Authors:  S M Clarke; F M Mulcahy; J Tjia; H E Reynolds; S E Gibbons; M G Barry; D J Back
Journal:  Br J Clin Pharmacol       Date:  2001-03       Impact factor: 4.335

6.  Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers.

Authors:  Sandra D Comer; Eric D Collins
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

Review 7.  Interactions between methadone and medications used to treat HIV infection: a review.

Authors:  M N Gourevitch; G H Friedland
Journal:  Mt Sinai J Med       Date:  2000 Oct-Nov

8.  Interaction of methadone with didanosine and stavudine.

Authors:  P M Rainey; G Friedland; E F McCance-Katz; L Andrews; S M Mitchell; C Charles; P Jatlow
Journal:  J Acquir Immune Defic Syndr       Date:  2000-07-01       Impact factor: 3.731

9.  The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects.

Authors:  Petrie M Rainey; Gerald H Friedland; Jerry W Snidow; Elinore F McCance-Katz; Susan M Mitchell; Laurie Andrews; Barbara Lane; Peter Jatlow
Journal:  Am J Addict       Date:  2002

10.  The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients.

Authors:  Elinore F McCance-Katz; Petrie M Rainey; Gerald Friedland; Peter Jatlow
Journal:  Clin Infect Dis       Date:  2003-08-01       Impact factor: 9.079
View more
  11 in total

1.  Gender differences in pharmacokinetics of maintenance dosed buprenorphine.

Authors:  David E Moody; Wenfang B Fang; Jerdravee Morrison; Elinore McCance-Katz
Journal:  Drug Alcohol Depend       Date:  2011-04-23       Impact factor: 4.492

Review 2.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

3.  Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.

Authors:  Aaron M Kipp; Andrew J Desruisseau; Han-Zhu Qian
Journal:  J Subst Abuse Treat       Date:  2011-02-24

4.  Important Drug-Drug Interactions in HIV-Infected Persons on Antiretroviral Therapy: An Update on New Interactions Between HIV and Non-HIV Drugs.

Authors:  Alice Tseng; Michelle Foisy
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

5.  Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Authors:  Qing Ma; Barry S Zingman; Amneris E Luque; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Robin DiFrancesco; Alan Forrest; Gene D Morse
Journal:  Ther Drug Monit       Date:  2011-06       Impact factor: 3.681

Review 6.  Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.

Authors:  Elinore F McCance-Katz; Lynn E Sullivan; Srikanth Nallani
Journal:  Am J Addict       Date:  2010 Jan-Feb

Review 7.  Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

Authors:  Valerie A Gruber; Elinore F McCance-Katz
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

8.  Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.

Authors:  Carmen L Masson; Petrie M Rainey; David E Moody; Elinore F McCance-Katz
Journal:  Am J Addict       Date:  2013-06-10

9.  Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.

Authors:  S Esser; A Haberl; F Mulcahy; J Gölz; A Lazzarin; E Teofilo; J Vera; A Körber; S Staszewski
Journal:  Eur J Med Res       Date:  2011-10-10       Impact factor: 2.175

10.  Tailored combination prevention packages and PrEP for young key populations.

Authors:  Audrey Pettifor; Nadia L Nguyen; Connie Celum; Frances M Cowan; Vivian Go; Lisa Hightow-Weidman
Journal:  J Int AIDS Soc       Date:  2015-02-26       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.